Tyra Biosciences (TYRA) News Today

Tyra Biosciences, Inc. (NASDAQ: TYRA) shares have moved lower as investors weigh a recent analyst downgrade against improved earnings forecasts from HC Wainwright. The downgrade appears to be the primary near-term pressure, while the broader analyst target of $46.89 suggests significant potential upside from recent trading levels.

• Positive Sentiment: Analysts have a consensus price target of $46.89 for Tyra Biosciences (TYRA), indicating substantial upside if the company meets expectations. Tyra Biosciences, Inc. Stock Has Consensus Price Target of $46.89
• Positive Sentiment: HC Wainwright raised its EPS forecasts across 2026 and 2027, including FY2026 losses of $2.60 per share versus a prior estimate of $2.86 and FY2027 losses of $2.27 versus $3.20 previously. The firm maintained a Buy rating and a $29 price target. The revised estimates imply expectations for narrower losses, although the company remains unprofitable.
• Neutral Sentiment: Reported short interest was listed at zero shares as of September 24, producing a 0.0-day short-interest ratio. This unusual figure provides little evidence of meaningful short-selling pressure and may reflect a reporting or data issue.
• Negative Sentiment: Tyra Biosciences shares declined after an analyst downgrade, adding immediate selling pressure and offsetting the more constructive HC Wainwright forecasts. The downgrade’s specific firm, rating change, and rationale were not provided in the available report. Tyra Biosciences Shares Down After Analyst Downgrade